概况

地位

技术

英文介绍

概况

武汉三鹰生物技术有限公司(Proteintech Group, Inc)是一家由留学人员和专业管理人员组成的新型生物技术外资企业，成立于2000年11月，2002年5月被认定为高新技术企业，是全国抗体生产公司的领头羊。公司总部和实验室设在武汉东湖新技术开发区关东科技园内，在美国和英国拥有自己的销售网络和网站（wwww.ptglab.com）。公司主要生产人类蛋白组抗体及相关产品。目前已有多克隆抗体10000多种，单克隆抗体300余种，融合蛋白13000多种，即已经完成了人类基因组三分之一以上的基因的表达，成为全球最大的重组蛋白生产公司。此外，公司还有人类全长cDNA 22000条，并拥有自己的实验动物基地。公司产品以出口为主，目前已在美、日、欧洲各国的生物医学领域拥有稳定的顾客群。

地位

武汉三鹰生物技术有限公司成立之初，即瞄准了蛋白质组研究这一巨大的市场，并提出了抗体组的概念。抗体是识别研究蛋白质必不可少的工具，三鹰生物的目标是实施人类抗体组计划，即研究和制备人类蛋白组中所有蛋白质的抗体，探索大规模制备抗体的新技术，并完善抗原－抗体相互作用的高通量化、自动化及智能化的检测技术。目前已经是国内最大的抗体公司，也是全球抗体公司中最大规模的公司之一。公司产品90%以上销往欧美地区，在同行业中占首位。

技术

武汉三鹰生物技术有限公司在美国设有专家顾问团，拥有强有力的技术支持后盾和培训力量；公司的骨干力量是一群朝气蓬勃的年轻人，武汉三鹰生物技术有限公司已经成功地将实验室的分子生物学技术，蛋白表达纯化技术，抗体纯化检测技术转化到产业化水平，技术涉足分子生物学，生物化学和免疫学等多个领域。目前公司的主要产品包括人类全长cDNA，纯化蛋白和抗体，已经推出免疫组化试剂盒，并正在研制一批高技术含量，高附加值的新产品。

英文介绍

The mission of Proteintech Group, Inc is to develop, manufacture a wide spectrum of antibodies against all human proteins known as Human Antibody Projects, thus providing the most effective tools for the identification and quantization of the vast number of known or unknown disease markers. Our philosophy is to be a part of the solution of the research community by providing scientists with every possible antibody they will need and at a reasonable cost. As all founders of the company are bench-side researchers, we have the deepest appreciation for the highest standard of perfection that all scientists hold for their projects, and therefore we hold our products to the same standard. As a part of this research community, we firmly committed to be a silent partner of every research laboratory and every research project.

Therefore it is the responsibility of Proteintech Group to offer researches with a variety of antibodies and related products at highest quality as possible so that the researchers can focus on their creativity, skill and effort as well as funding, without ever having to concern with the quality of reagents used. We also committed to provide them at lowest possible cost because we understand that every dollar of the research grant is the result of hard work of the researchers. Every dollar we saved is a dollar they have earned.

As the silent partner in your research career, you can count on us to solve your supply and technical needs on antibodies and antibody related products. We deeply understand that only if you succeed, we will succeed.

Proteintech Group offers a variety of polyclonal and monoclonal antibodies for your research. Each antibody is thoroughly tested for its ability to perform immunoprecipitation, immunoblotting and immunohistochemistry so that you can be confident in using them. Understanding each antibody has its unique applications and features, we also provide our customers with complete technical support and detailed instructions for each application. To maximize your research flexibility, we promise following services.

The antibody and antibody-related products for research, biotech and clinical diagnostics constitute huge but unsaturated market in the world, and it is subject to a high growth trend. In the US, the National Institute of Health alone receives 17 billion dollars federal funding, among that, 1.7 billion, i.e. 10% is spent on antibody and related reagents. Many private pharmaceutical companies spent many fold more on antibodies and its related products. Another growing market is the proteomic project (project to identify, profile all human proteins and their function), especially in the post genomic project period. Antibodies are the only type of reagents today to solve most problems in the Human Proteomic Project. It is estimated that some 300,000 different anti-human protein antibodies will be needed while there are only 10,000 Antigen specificities are available.

The mission of the Proteintech Group is to design, develop, and market antibody and antibody-chips in the Bioresearch field. The antibody will fill current market that accounts for a minimum of $ 1.7 billion dollars in potential sales. Each product shall be priced to appeal to researchers that stresses lowest cost and convenient.

The procedure of production and marketing has been tested. Projections from studies have shown that with a 2 million dollar initial investment, the company would expect $24 million in sales in year three with a net profit of approximately $20 million. The company would expect to have $38 million in revenue by year five. The company would be self sustained in year one and will be able to break even between year one and two, purely based on antibody production and sales.

In next five years, the estimated market of products yielded from proteomic project would reach to 40 billion. The Proteintech Group is currently developing antibody chips (a collection of thousand antibodies arranged in arrays for quick identification and quantitation of known or unknown proteins in a mixture, such as in blood), a key product of this market. With its advantages of it.